Apitolisib - CAS 1032754-93-0
Catalog number:
1032754-93-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
mTOR
Description:
Apitolisib, also known as GDC-0980 and RG7422;  or GNE390, is a dual PI3 kinase/mTOR inhibitor,   is also an orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor GDC-0980 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion.
Publictions citing BOC Sciences Products
  • >> More
Appearance:
white solid powder
Synonyms:
GDC-0980; GDC0980; GDC 0980; RG7422; RG-7422; RG 7422; GNE 390; GNE390; GNE-390; Apitolisib
MSDS:
Inquire
Current Developer:
Roche/Genentech.
1.Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Dolly SO1, Wagner AJ2, Bendell JC3, Kindler HL4, Krug LM5, Seiwert TY4, Zauderer MG5, Lolkema MP6, Apt D7, Yeh RF7, Fredrickson JO7, Spoerke JM7, Koeppen H7, Ware JA7, Lauchle JO7, Burris HA3, de Bono JS8. Clin Cancer Res. 2016 Jan 19. [Epub ahead of print]
PURPOSE: This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I PI3K, and mTOR kinases.
2.A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma.
Ding X1, Li F2, McKnight J2, Schmidt C2, Strooisma K2, Shimizu H3, Faber K4, Ware JA4, Dean B5. J Pharm Biomed Anal. 2014 Nov;100:150-6. doi: 10.1016/j.jpba.2014.08.001. Epub 2014 Aug 10.
A liquid chromatographic-tandem mass spectrometry (LC-MS/MS) method for the determination of GDC-0980 (Apitolisib) concentrations in human plasma has been developed and validated to support clinical development. Supported liquid extraction (SLE) was used to extract plasma samples (80μL) and the resulting samples were analyzed using reverse-phase chromatography and mass spectrometry coupled with a turbo-ionspray interface. The mass analysis of GDC-0980 was performed using multiple reaction monitoring (MRM) transitions in positive ionization mode. The method was validated over the calibration curve range 0.0500-25.0ng/mL using linear regression and 1/x(2) weighting. Within-run relative standard deviation (%RSD) ranged from 0.4 to 3.9%, while the between-run %RSD varied from 1.1 to 1.5% for QCs. The accuracy ranged from 96.1% to 106.7% of nominal for within-run and 96.7-106.7% of nominal for between-run at all concentrations including the LLOQ quality control at 0.
3.Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study.
Ding X1, Salphati L1, Kim A2, Morinello E2, Wong L2, Pang J1, Percey S3, Meng M3, Reuschel S3, Dean B1. Biomed Chromatogr. 2015 Aug;29(8):1274-9. doi: 10.1002/bmc.3417. Epub 2015 Feb 10.
An LC-MS/MS method for the determination of GDC-0980 (apitolisib) concentrations in dog plasma has been developed and validated for the first time to support pre-clinical drug development. Following protein precipitation with acetonitrile, the resulting samples were analyzed using reverse-phase chromatography on a Metasil AQ column. The mass analysis was performed on a triple quadruple mass spectrometer coupled with an electrospray interface in positive ionization mode. The selected reaction monitoring transitions monitored were m/z 499.3 → 341.1 for GDC-0980 and m/z 507.3 → 341.1 for IS. The method was validated over the calibration curve range 0.250-250 ng/mL with linear regression and 1/x(2) weighting. Relative standard deviation (RSD) ranged from 0.0 to 10.9% and accuracy ranged from 93.4 to 113.6% of nominal. Stable-labeled internal standard GDC-0980-d8 was used to minimize matrix effects. This assay was used for the measurement of GDC-0980 dog plasma concentrations to determine toxicokinetic parameters after oral administration of GDC-0980 (0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mTOR Products


CAS 1223002-54-7 QL-IX-55

QL-IX-55
(CAS: 1223002-54-7)

The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiase...

GDC-0084
(CAS: 1382979-44-3)

GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...

AZD-3147
(CAS: 1101810-02-9)

AZD-3147 is an extremely potent and selective dual inhibitor of mTORC1 and mTORC2. It exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. It has ...

CAS 1197160-78-3 Gedatolisib (PF-05212384, PKI-587)

Gedatolisib (PF-05212384, PKI-587)
(CAS: 1197160-78-3)

Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Phase 2.

CAS 1062161-90-3 WYE-687

WYE-687
(CAS: 1062161-90-3)

WYE-687 is a potent and ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM.

CAS 1013101-36-4 PF-04691502

PF-04691502
(CAS: 1013101-36-4)

PF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the...

CAS 1246535-95-4 Desmethyl-VS-5584

Desmethyl-VS-5584
(CAS: 1246535-95-4)

Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.

CAS 1092351-67-1 PP242

PP242
(CAS: 1092351-67-1)

PP242 is a novel potent and selective mTOR inhibitor with an IC50 of 8 nM. PP242 also shows residual (micromolar) activity against panel of tyrosine kinases. Bu...

CAS 53123-88-9 Rapamycin

Rapamycin
(CAS: 53123-88-9)

Rapamycin is a mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcripti...

CAS 1009298-09-2 AZD-8055

AZD-8055
(CAS: 1009298-09-2)

AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/t...

CAS 326914-06-1 MHY1485

MHY1485
(CAS: 326914-06-1)

mTOR activator with an inhibitory effect on autophagy. MHY1485 markedly increased the LC3II/LC3I ratio dose-dependently and time-dependently by inhibition of th...

CAS 914913-88-5 Palomid 529

Palomid 529
(CAS: 914913-88-5)

Palomid 529, also known as P529, is a novel PI3K/Akt/mTOR inhibitor. Palomid 529 (P529) inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt ...

CAS 936890-98-1 OSI-027

OSI-027
(CAS: 936890-98-1)

mTOR kinase inhibitor OSI-027 is an orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinas...

CAS 1173204-81-3 PKI-402

PKI-402
(CAS: 1173204-81-3)

PKI-402 is a selective, reversible, ATP-competitive, equipotent inhibitor of class I phosphatidylinositol 3-kinases (PI3K), including PI3K-alpha mutants, and ma...

CAS 572924-54-0 Ridaforolimus

Ridaforolimus
(CAS: 572924-54-0)

Ridaforolimus is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus bin...

CAS 1224844-38-5 MLN0128

MLN0128
(CAS: 1224844-38-5)

MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...

ABTL-0812
(CAS: 57818-44-7)

ABTL-0812 is an orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR), rictor-mTOR and dihydrofolate reductase with p...

CAS 934493-76-2 Voxtalisib (XL-765)

Voxtalisib (XL-765)
(CAS: 934493-76-2)

SAR245409 (XL765) is a potent and highly selective pan inhibitor of class I PI3Ks (α/β/γ/δ, IC50=39/110/9/43 nM) with activity against mTOR(IC50=160-910 nM).

CC-115 hydrochloride
(CAS: 1300118-55-1)

The hydrochloride salt form of CC-115 which is a mTOR / DNA-PK inhibitor that probably has antineoplastic effect through influencing the cellular proliferation ...

CAS 1092788-83-4 PP121

PP121
(CAS: 1092788-83-4)

PP121 is a multitargeted dual receptor tyrosine kinases inhibitor. PP121 blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kin...

Chemical Structure

CAS 1032754-93-0 Apitolisib

Quick Inquiry

Verification code

Featured Items